Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japanã- Results From Post-Marketing Surveillance (XASSENT).

Fukuda, Ikuo; Hirayama, Atsushi; Kawasugi, Kazuo; Kobayashi, Takao; Maeda, Hideaki; Nakamura, Mashio; Yamada, Norikazu; Tajima, Tsubasa; Tachiiri, Michiya; Okayama, Yutaka; Sunaya, Toshiyuki; Hirano, Kazufumi; Hayasaki, Takanori

Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japanã- Results From Post-Marketing Surveillance (XASSENT).

Fukuda, Ikuo; Hirayama, Atsushi; Kawasugi, Kazuo; Kobayashi, Takao; Maeda, Hideaki; Nakamura, Mashio; Yamada, Norikazu; Tajima, Tsubasa; Tachiiri, Michiya; Okayama, Yutaka; Sunaya, Toshiyuki; Hirano, Kazufumi; Hayasaki, Takanori.

Afiliação

Fukuda I; Department of Cardiology, Keimeikai Yokawa Hospital.
Hirayama A; Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital.
Kawasugi K; Department of Internal Medicine, Teikyo University School of Medicine.
Kobayashi T; Department of Obstetrics and Gynecology, Hamamatsu Medical Center.
Maeda H; Heart and Vascular Center, Ukima Central Hospital.
Nakamura M; Nakamura Medical Clinic.
Yamada N; Department of Cardiology, Kuwana City Medical Center.
Tajima T; Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd.
Tachiiri M; Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd.
Okayama Y; Pharmacovigilance Monitoring and Governance, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd.
Sunaya T; Statistics and Data Insights, Data Sciences and Analytics, Research and Development Japan, Bayer Yakuhin, Ltd.
Hirano K; Pharmacovigilance Monitoring and Governance, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd.
Hayasaki T; Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd.

Circ J ; 87(9): 1175-1184, 2023 08 25.

Article em En | MEDLINE | ID: mdl-37245989

Assuntos

Embolia Pulmonar; Tromboembolia Venosa; Humanos; Idoso; Rivaroxabana/efeitos adversos; Tromboembolia Venosa/tratamento farmacológico; Tromboembolia Venosa/epidemiologia; Anticoagulantes/efeitos adversos; Japão/epidemiologia; Estudos Prospectivos; Resultado do Tratamento; Embolia Pulmonar/tratamento farmacológico; Embolia Pulmonar/epidemiologia; Embolia Pulmonar/induzido quimicamente; Hemorragia/induzido quimicamente; Hemorragia/epidemiologia; Vigilância de Produtos Comercializados

Palavras-chave

Deep vein thrombosis; Japan; Pulmonary embolism; Rivaroxaban; Venous thromboembolism

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Tromboembolia Venosa Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Aged / Humans País/Região como assunto: Asia Idioma: En Revista: Circ J Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google